



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

1.	Dr. Kartar Dawani Pro-V.C	Pro V.C/ Chairman	 18/01
2.	Prof Amir Awi	M.S. - DUH	 18/01
3.	Aame Haid	Manager Pharmacy DUH	 18/1/2020
4.	Dr. Arjuz Zubedi	Add. M.S Dr. R.K.M.P. CHC	
5.			
6.	Nafeesul Hassan	Deputy Director Finance	 18/1 Nafeesul Hassan Khan DEPUTY DIRECTOR FINANCE

Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
1	M/s. National Agencies	N. Biled	Field	0345-2274577	B. Biled
2	M/s. Care and Cure Marketing Services	M. Saad Zaki	Sales Manager	0333 22-13184	M. Saad Zaki
3	M/s. R & A Enterprises	Sajid Ali	institutional manager	0331-1322236	w. e. p.
4	M/s. Ace Enterprises	Imran	ASST. Manager	0323-240242	Imran
5	M/s. Waseem Brothers	N. NAGAR	Executive Techn Services	0333-2275778	N. Nagar
6	M/s. Shadani Enterprises	A. Shadani			

18/01/2020

**DR. ALI A. ZUBEDI**  
Addl. Medical Superintendent  
(Antimicrobial)  
Dow University of Health Sciences  
Karachi

**PROF. DR. KAMRAN DAWAN**  
Vice-Chancellor  
Dow University of Health Sciences  
Karachi

**DEPUTY DIRECTOR FINANCE**  
Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

**Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items**

**NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019**

**OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020**

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
7	M/s. Trade Link	Ovais Ali	Business Development Manager	0321-3806044	
8	M/s. Ali Gohar & Company (Pvt.) Ltd.	M. Arifal Khan	Institutional Sales Manager	0323-2708400	
9	M/s. Sami Pharmaceuticals (Pvt.) Ltd.	Muhammad Akif	S.N.S.M Institutional Managers	0300-8262919	
10	M/s. R.K. Chemical Company	M. Jameel	Manager Admin	0313-3660579	
11	M/s. Medic International	Abid ul Haq	Sele	03122697277	
12	M/s. Hassaan Distribution	absent			

18/01/2020

**PROF. DR. KARIM DAWANI**  
Pro. Vice-Chancellor  
Dow University of Health Sciences  
Karachi

**DEPUTY DIRECTOR FINANCE**  
Dow University of Health Sciences  
Karachi

**DR. AJMAL ZUBEDI**  
Add. Medical Superintendent  
(Admin)  
Dr. Rubi K. P. S. Civil Hospital Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
13	M/s. Intra Health	Syed Saqib Ali	Manager	03343772362	
14	M/s. United Agencies	Shakee Ahmad	Liaison Offr	0332 3577 211	
15	M/s. Onco Pharma	absent			
16	M/s. Onco One	absent			
17	M/s. Jawed Traders	M. SIDDIQ	Sales & Recovery Manager	0333-2179719	
18	M/s. Hiranis Pharmaceutical (Pvt.) Limited	A. Sameed	R.O.M.S.	03002799231	

Teaching Staff  
Disqualified

18/01/2020  
YASMINI  
18/01

DR. MUJAZ ZUBEDI  
Deputy Director Finance  
Dow University of Health Sciences  
Karakoram

ASGHAR M. HASSAN KHAN  
DEPUTY DIRECTOR FINANCE  
Dow University of Health Sciences  
Karakoram



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
19	M/s Roche Pakistan	WARAR-ABBAS	DISTRIBUTION OFFICER	03002043844	
20	M/s. Shamim & Co.	Sibt-Gul	BDM	03331214326	
21	M/s. Hussain Traders	M. Shehina	ASSA	0315-8684965	
22	M/s. Medco Health Care	Imran	Sale officer	0321-9795694	
23	M/s. Hakimsons (Impex) Private Ltd.	Imtiaz Aheer	Field Mouny	0301-8246806	
24	M/s. Spectrum Medical Supplies	RASHID	Sales Manager	0332270767	

PROF. DR. KARTAR DAWAR  
Pro Vice-Chancellor  
Dow University of Health Sciences  
Karachi

18/01/20

M. C. Masood Khan  
DEPUTY DIRECTOR FINANCE  
Dow University of Health Sciences  
Karachi

18/01/20



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
25	M/s. Pioneer Distributors	S. GHORAS.	Asst manager sales	03360850797.	
26	M/s. Z. I Enterprises	absent			
27	M/s. Karachi Medical Company	Syeda Azhar Ali	B.U.M	0321 8226013	
28	M/s. Popular International (Pvt.) Ltd.	M. Naved	S.P.O	03002773977	
29	M/s. Gulf Pharmaceuticals	absent			
30	M/s. Global Pharmaceuticals (Pvt.) Ltd.	absent			

Technical X  
Disqualified

DR. M. HANIS AMIN  
Deputy Director Finance  
Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items  
NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
31	M/s. Vision Pharmaceuticals (Pvt.) Ltd.	absent			
32	M/s. Allmed Laboratories	M. Naved aliqab	Regional Manager	03322597250	Naved
33	M/s. Lavish Enterprises	absent			
34	M/s. Faraz Associates	M. Hani ul Haq	Manager Sales & Marketing	03458244317	Hani
35	M/s. Gratton Pharma	Rashid Jafri	Area Sales Manager	03463636242	MX JV
36	M/s. Lab Link Enterprises	MR WABAR ALAMI	D. K. R	0332-0297326	

Technical X  
in compliance

DR. ALI A. ZUBEDI  
Add: Medical Superintendent  
(Admin)  
Dr. Rashid K.K. Pk. Civil Hospital Karachi

PROF. DR. KARTAR DAWANI  
Pro - Vice Chancellor  
Dow University of Health Sciences  
Karachi

PROF. M. HASSAN KHATTAR  
DEPUTY DIRECTOR FINANCE  
Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
37	M/s. Phamasol (Pvt.) Ltd.	Syed Farooq Ahmed	P.S	03051-8205392-	
38	M/s. Aster Life Sciences	Syed ATIF HUSSAIN	SSM	0345-8185644	
39	M/s. Hoffmann Human Health Pakistan Limited	Syed ATIF HUSSAIN	SSM	0345-8185644	
40	M/s. Bosch Pharmaceuticals (Pvt.) Ltd.	M. SALAHUDDIN	ADUM	0321 2622772	
41	M/s. Al Habib Pharmaceuticals	Azjad Khan	Asst Mgr. Sales Mktg.	0342-1116728.	
42	M/s. Muller & Phipps Pakistan (Private) Limited.	S. TAOI HANZA M.I. S.O		0336686470	

DEPUTY DIRECTOR FINANCE  
University of Health Sciences  
Karachi

PROF. DR. FARHAT DAWANI  
Prof. Vice-Chancellor

DR. ALIM ZUBERI  
Asst. Registrar (Academic)  
University of Health Sciences  
Karachi

Dr. Alim Zuberi  
Asst. Registrar (Academic)  
University of Health Sciences  
Karachi





# DOW UNIVERSITY OF HEALTH SCIENCES ATTENDANCE SHEET

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT NO. DUHS/DP/2019/77 DATED 8<sup>th</sup> August, 2019

OPENING OF FINANCIAL OFFERS ON 18<sup>th</sup> JANUARY, 2020

S. #	Bidder (Company / Firm / Contractor)	Representative (Name)	Designation	Contract Number	Signature
43	M/s. Pharmawell Pvt. Ltd.				
44	M/s. Saad Sales Services	Awarab	Manager	03062216584	
45	M/s. Hamza Enterprises				
46	M/s. Hospital Solution	Haris Arimed	Marketing.	03144-2246461	
47	M/s. Mabro International	Ahnan khusro	Field Manager	03332369047	

Technical  
Remarks

PROF. DR. KARTAR DAWAR  
Vice Chancellor  
Dow University of Health Sciences  
Karachi

18/10/20



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET (Procurement Committee)

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No:DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	NAME	DESIGNATION	SIGNATURE
	Dr. Kasim Dawood	Pro VC.	
	Dr. Ayaz Rubedi	Addl. M.S Dr. R.K.M.P. - CHK	
	Muhammad Haqif	Additional Director Finance	
	IFFAT SWAMIR	CHIEF OPERATING OFFICER	
	Asma Harid	Manager Pharmacy	
	Pwj Hussain	M.S DUIT	

Est: 4308 Ismail Juma



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No: DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	BIDDER (Company / Firm / Contractor)	REPRESENTATIVE (Name)	DESIGNATION	CONTACT NUMBER	SIGNATURE
1.	Hironis Pharma	Abdul Samid	Manager Sales	03002799231 021-34373296	<i>[Signature]</i>
2	Ali Gohar 2 Company (Pvt). Ltd.	Muhammad Ajmal Khan	Institutional Sales Manager	0323-270840	<i>[Signature]</i>
3	Sawi Pharma	AZIF ALBEM KATTAH	S. A. I. M	0333-109585	Aj Alben
4	R.K Chemical Co	Muhammad Tawid	Manager Admin	0313-3660579	<i>[Signature]</i>
5	Hassam Distributions	Faham	Area manager	0332-3646256	<i>[Signature]</i>
6	JAWED TRADERS	M. SIDDIQ	Sales Recovery Manager	0333-2179779	<i>[Signature]</i>
7	Aaboo Int	Ahwan Khurshed	Field Manager	0333236017	<i>[Signature]</i>
8	Saad Sales Service	ABDUL GHAFAR	I.M.	0321 22128220	<i>[Signature]</i>

*[Handwritten signature and notes]*

DR. ALJANAH (M.D.)  
Asst. Medical Superintendent  
Dr. Rubi K.M. Khan (M.B.B.S.)  
Hospital Karachi

Yasmin  
PROF. DR. KASTAR DAWANI  
Pro. Vice Chancellor  
Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No: DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	BIDDER (Company / Firm / Contractor)	REPRESENTATIVE (Name)	DESIGNATION	CONTACT NUMBER	SIGNATURE
9.	HAMZA Enterprises	Wahed	M.D	0300300799	<i>[Signature]</i>
10.	RDA Enterprises	Sajid Ali	insultant manager	0331-1322236	<i>[Signature]</i>
11.	BOSCH	AARTI SHAH	Sales Manager.	0390-3231802	<i>[Signature]</i>
12.	Z.T Enterprises	Sayan Ahmad	Supply chain Top, Manager	0345-5476414	<i>[Signature]</i>
13.	CARE ANS CARE	Muhammad Amir	Business Manager.	0306-777748	<i>[Signature]</i>
14.	Coastal E. Sp.	Rajeshwari	—	0301-244100	<i>[Signature]</i>
15.	Pioneer Distributors	M. Ravi Kumar	Manager.	0300920574	<i>[Signature]</i>
16.	Graton Pharma	Alzija Ishtiaq	Sales Manager	0346 3636318 0331 8905211	<i>[Signature]</i>

DR. AIJAZ ZUBAIR  
Asst. Medical Superintendent  
(Admin. & Finance)  
Dr. Raft K.A. Purohit  
Jointly For

*[Signature]*  
Dr. Raft K.A. Purohit

*[Signature]*  
Dr. Raft K.A. Purohit

AR

Dr. Raft K.A. Purohit  
Jointly For



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No: DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	BIDDER (Company / Firm / Contractor)	REPRESENTATIVE (Name)	DESIGNATION	CONTACT NUMBER	SIGNATURE
17	Medic International	Abid ali Khan	Sels officer	03122697277	
18	AL HABIB PHARMA	Asif Asif	BUH	0345-3511804	
19	<del>QARS</del> <del>Ali</del> (TRADELINK)	Omair Ali	BDM	0321-3801044	
20	Faraz Associates	M. Harris ul Haq	Manager Sales & Mkt	03458244317	
21	Shamim Bco	Mis Gul	BDM	0333-1214326	
22	INASEEM BROTHERS	M. NAQAR	Executive Tender Bids	0333-2275778	
23	Aston Life Sciences	S. ATIF HUSSAIN	S.M (South)	0345-8185644	
24	Hoffmann Human Health	S. ATIF HUSSAIN	S.M (South)	0345-8185644	

DR. AIJAZ A. QURESHI  
Add. Medical Superintendent  
(Admin)  
Dr. Rashid M. Pali Civil Hospital, Karachi

PROF. DR. KARIM DURRANI  
Pro. Vice-Chancellor  
Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No: DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	BIDDER (Company / Firm / Contractor)	REPRESENTATIVE (Name)	DESIGNATION	CONTACT NUMBER	SIGNATURE
25	United Agencies	Shakeel Ahmad	Co-ordinator officers,	0332 3099211	
26	SPECTRUM MEDICAL SUPPLIES	Rashid. A. Kady	Sales Manager	0333 2270767	
27	Shadani Enterprises	Yameen Hussain	MANAGER	0334 3494435	
28	Karachi Medical Company	Suhail	Sales Officer	0300724562	
29	ALLIED LABORATORIES	Imran Khan	DIRECTOR	0332-2597250	
30	HUSSAIN Textiles	M. Yousaf	ARTIST	0315-8654865	
31	Polaris International	Mohammed Naveed	S. P.O	0300-2773977	
32	Global Pharma	Hafiz Anjum	Sales Manager	0300306614	

DR. ALI RAZA SIDDI  
Add: Medical Superintendent  
(NIT) No: DUHS/DP/2019/-77  
Dr. Rosh K.M. Ph.D. (Hospital Karachi)

Wazir

PROF. DR. FAHIM DAWANI  
Pro. Vice Chancellor  
Dow University of Health Sciences  
Karachi



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No: DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	BIDDER (Company / Firm / Contractor)	REPRESENTATIVE (Name)	DESIGNATION	CONTACT NUMBER	SIGNATURE
33	National Agencies	M. Bilal	Field	0321-8239196	Bilal
34	ACE ENTERPRISE	Imran	ASST. Manager	0323-2401242	Imran
35	Vistival Pharms	Munseer Hameed	Head Pharmacist	03000306614	Munseer Hameed
36	IMTIAZ HANIMSON (IMPES)	MR. IMTIAZ	INS. MANAGER	0301-8246806	Imtiaz
37	LAB LINK ENTERPRISE	LAGAR	District Sales	0332-0257326	Gar
38	ONCO PHARMA	BURHAN	MAN. Rep	0300-3273671	Burhan
39	ONCA ONE	BURHAN	" "		Burhan
40	PHARMA WELC	BURHAN	" "		Burhan

Munseer Hameed

DR. ALJAZ ZUBEDI  
Add: Medical Sciences Building  
(AUGUST 2019)  
Dr. Rubh K.M. Pkss Govt Hospital Karachi

YES I AM  
PROF. DR. KAMRAN DAWANI  
Pro Vice Chancellor  
Dow University of Health Sciences  
Karachi

Imtiaz



# DOW UNIVERSITY OF HEALTH SCIENCES

## ATTENDANCE SHEET

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA AND ALLIED ITEMS

Invitation for Bid (NIT) No: DUHS/DP/2019/-77 Dated 08 AUGUST, 2019

OPENING OF TECHNICAL BIDS / PROPOSALS ON 17 SEPTEMBER, 2019 AT 11:30 A.M.

S#	BIDDER (Company / Firm / Contractor)	REPRESENTATIVE (Name)	DESIGNATION	CONTACT NUMBER	SIGNATURE
41	ROOPE PARISTON	SARVIB / WAQAR	SR. SALES MGR.	03219066690	<i>[Signature]</i>
42	Hospital Solutions	Sh. Nadeem	Sales mcr	0306-0025771	<i>[Signature]</i>
43	Gulpharma	Shahryar Swacha	Marketing Representative	0300-2557537	<i>[Signature]</i>
44	Zairea Harch	Syed Saad Ali	A.S.M	0334 3772360	<i>[Signature]</i>
45	Macleods Pharmaceuticals	Syed. Ahmad Ali	A.S.M	03002348545	<i>[Signature]</i>
46	Medco Health Care	Atif Ahmed	Director	0321-9295694	<i>[Signature]</i>
47	Pharma Sol	Syed Fawad Armes	P-S	0307-820372	<i>[Signature]</i>
48	Agma Muzesi Adam	Amrout Ali	BDR	0333-3112522	<i>[Signature]</i>

*[Handwritten notes and signatures]*  
 Bid of Muzesi Adam & Sons returned unopened due to reason that tender not purchased against the Drug Medicines  
 Syed Muzesi Adam & Sons  
 Syed Muzesi Adam & Sons  
 Syed Muzesi Adam & Sons



**MINUTES OF FINANCIAL BID OPENING MEETING**

NIT No.	DUHS / DP / 2019 /-77 Dated: 8 <sup>th</sup> August, 2019
SPPRA (PPMS website)	Sr. # T00582-19-0002
Method and procedure of procurement	Single Stage – Two Envelope Procedure SPP Rules – 46(2)

**PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA & ALLIED ITEMS DOW UNIVERSITY OF HEALTH SCIENCES, KARACHI**

Meeting of the Procurement Committee (PC) held for opening of **Financial Bids** on **18<sup>th</sup> January, 2020** in respect of subjected NIT. Meeting was attended by members of the Procurement Committee and representative of bidders. (**Attendance sheets are enclosed**).

The Bids were opened on 18.01.2020 at 11:00 a.m. in presence of all participants. The rates quoted by bidders were read aloud by Chairman of the Procurement Committee. All the members of Procurement Committee signed each and every page of Financial Proposal / Bids. The bids do not contain any over-writing or cutting.

Offers of the following four (04) bidders were technically disqualified / not approved by the Technical Evaluation Committee:

1. M/s Hirani Pharmaceuticals (Pvt) Ltd.,
2. M/s Vision Pharmaceuticals (Pvt) Ltd.,
3. M/s Pharmawell (Pvt) Ltd.
4. M/s Gulf Pharmaceuticals

Following is the detail of technically qualified bidders:

Sr.#	Name of Bidder	Amount of Bid Security (2%) in Pak. Rs	Pay Order No. / Date
1	M/s. Ali Gohar & Company (Pvt.) Ltd.	355,610.00	PO# 06867484; Dated: 17-9-2019 (Bank Al Habib)
2	M/s. Sami Pharmaceuticals (Pvt.) Ltd.	399,600.00	PO# 13546788; Dated: 3-9-2019 (Habib Metropolitan)
3	M/s. R.K. Chemical Company	2,149,485.00	PO# 13288915; Dated: 16-9-2019 (Habib Metropolitan)
4	M/s. Hassaan Distribution	25,000.00	PO# 147039; Dated: 16-9-2019 (Bank Islami Pak)
5	M/s. Jawed Traders	230,000.00	PO# 1051012817; Dated: 16-9-2019 (Al Baraka Bank)
6	M/s. Mabro International	380,000.00	PO# 05341502; Dated: 16-9-2019 (Faysal Bank)
7	M/s. Saad Sales Services	290,000.00	PO# 13288923; Dated: 16-9-2019 (Habib Metropolitan)
8	M/s. Hamza Enterprises	650,000.00	CDR# 00060981; Dated: 16-9-2019 (Dubai Islamic Bank)
9	M/s. R & A Enterprises	1,221,138.00	PO# 05905207; Dated: 17-9-2019 (Meezan Bank)
10	M/s. Bosch Pharmaceuticals (Pvt.) Ltd.	1,400,000.00	PO# 06712941; Dated: 12-9-2019 (UBL Ltd)
11	M/s. Z. I Enterprises	400,000.00	PO# 06534284; Dated: 16-9-2019 (Bank Al Habib)
12	M/s. Care and Cure Marketing Services	300,000.00	PO# 05544191; Dated: 14-9-2019 (Meezan Bank)

DR. AMR A. JIBRIL  
 Head Medical Superintendent  
 Dow University of Health Sciences  
 Karachi

Y. Q. Khan  
 Head of Procurement  
 Dow University of Health Sciences  
 Karachi

Y. Q. Khan  
 Deputy Director Finance  
 Dow University of Health Sciences  
 Karachi

Sr.#	Name of Bidder	Amount of Bid Security (2%) in Pak. Rs	Pay Order No. / Date
13	M/s. Lavish Enterprises	300,000.00 200,000.00	CDR# 096226; Dated: 14-9-2019 (National Bank Pak) CDR# 096227; Dated: 14-9-2019 (National Bank Pak)
14	M/s. Pioneer Distributors	131,238.00	PO# 22506588; Dated: 5-9-2019 (Habib Bank Ltd)
15	M/s. Graton Pharma	12,868.00 1,098,000.00 272,000.00	PO# 655340; Dated: 16-9-2019 (JS Bank) PO# 655341; Dated: 16-9-2019 (JS Bank) PO# 655342; Dated: 16-9-2019 (JS Bank)
16	M/s. Medic International	300,000.00	PO# 15566774; Dated: 16-9-2019 (UBL Ltd)
17	M/s. Al Habib Pharmaceuticals	77,400.00	PO# 22704460; Dated: 16-9-2019 (Habib Bank Ltd)
18	M/s. Trade Link	2,914,000.000	PO# 008592; Dated: 16-9-2019 (Bank Alfalah)
19	M/s. Faraz Associates	130,000.00	PO# 5840228; Dated: 16-9-2019 (Meezan Bank)
20	M/s. Shamim & Co.	800,000.00 800,000.00 477,743.00 20,000.00	PO# 12319424; Dated: 16-9-2019 (Allied Bank) PO# 12319426; Dated: 16-9-2019 (Allied Bank) PO# 12319432; Dated: 16-9-2019 (Allied Bank) PO# 14697192; Dated: 17-9-2019 (Allied Bank)
21	M/s. Waseem Brothers	259,759.00	PO# 13261459; Dated: 7-9-2019 (Habib Metropolitan)
22	M/s. Aster Life Sciences	457,189.00	PO# 06854122; Dated: 16-9-2019 (Bank Al Habib)
23	M/s. Hoffmann Human Health Pakistan Ltd.	1,371,341.00	PO# 06854123; Dated: 16-9-2019 (Bank Al Habib)
24	M/s. United Agencies	1,200,000.00 176,000.00 660,000.00 8500.00 660,000.00 285,000.00 115,000.00	PO# 21427378; Dated: 3-9-2019 (Habib Bank Ltd) PO# 21427379; Dated: 3-9-2019 (Habib Bank Ltd) PO# 21427380; Dated: 3-9-2019 (Habib Bank Ltd) PO# 21427381; Dated: 3-9-2019 (Habib Bank Ltd) PO# 21427382; Dated: 4-9-2019 (Habib Bank Ltd) PO# 21427384; Dated: 5-9-2019 (Habib Bank Ltd) PO# 21427399; Dated: 13-9-2019 (Habib Bank Ltd)
25	M/s. Spectrum Medical Supplies	216,000.00	PO# 13141819; Dated: 17-9-2019 (Habib Metropolitan)
26	M/s. Shadani Enterprises	402,000.00	PO# 14522837; Dated: 17-9-2019 (Allied Bank)
27	M/s. Karachi Medical Company	500,000.00	PO# 05869389; Dated: 16-9-2019 (Meezan Bank)
28	M/s. Allmed Laboratories	457,000.00	PO# 4533483; Dated: 2-9-2019 (Standard Chartered)
29	M/s. Hussain Traders	1,100,000.00	PO# 1012818; Dated: 17-9-2019 (Al Baraka)
30	M/s. Popular International (Pvt.) Ltd.	490,000.00	PO# 21860264; Dated: 16-9-2019 (Habib Bank Ltd)
31	M/s. Global Pharmaceuticals (Pvt.) Ltd.	555,817.00	CDR# 1818048; Dated: 30-8-2019 (MCB)
32	M/s. National Agencies	1,400,000.00 950,000.00	PO# 267190; Dated: 16-9-2019 (MCB Islamic Bank) PO# 21991031; Dated: 16-9-2019 (Habib Bank Ltd)
33	M/s. ACE Enterprises	673,928.00	PO# 5499448; Dated: 16-9-2019 (Soneri Bank)
34	M/s. Hakimsons (Impex) Private Ltd.	320,361.00	PO# 22581608; Dated: 13-9-2019 (Habib Bank Ltd)
35	M/s. Lab Link Enterprises	1,000,000.00	CDR# 70503787; Dated: 16-9-2019 (Summit Bank)
36	M/s. Onco Pharma	150,200.00	PO# 15019906; Dated: 16-9-2019 (Allied Bank)


**PROF. DR. KARTAR DAWANI**  
 Pro-Vice Chancellor  
 Dow University of Health Sciences  
 Karachi

  
**DEPUTY DIRECTOR FINANCE**  
 Dow University of Health Sciences  
 Karachi.

Sr.#	Name of Bidder	Amount of Bid Security (2%) in Pak. Rs	Pay Order No. / Date
37	M/s. Onco One	280,500.00	PO# 21015417; Dated: 16-9-2019 (Habib Bank Ltd)
38	M/s. Roche Pakistan	5,572,260.00	DD# 36438; Dated: 3-9-2019 (Citi Bank)
39	M/s. Hospital Solution	213,000.00	PO# 5346994; Dated: 17-9-2019 (Faysal Bank)
40	M/s. Intra Health	346,500.00	PO# 6525914; Dated: 16-9-2019 (Bank Al Habib)
41	M/s. Muller & Phipps Pakistan (Private) Ltd.	323,311.00	PO# 327654; Dated: 13-9-2019 (Samba Bank)
42	M/s. Medco Health Care	195,500.00	PO# 6666813; Dated: 16-9-2019 (Bank Al Habib)
43	M/s. Phamasol (Pvt.) Ltd.	315,000.00	BG# BAML/0043/09/2019 (Bank Al Habib)

The meeting ended with the vote of thanks.



**Dr. Ajaz Zubedi**

Additional Medical Superintendent (Admin)  
Dr. Ruth K.M Pfau, Civil Hospital – Karachi  
(Member)

**DR. AJAZ A. ZUBEDI**  
Add: Medical Superintendent  
(Admin)  
Dr. Ruth K.M. Pfau Civil Hospital Karachi




**Representative of Finance Directorate**  
Dow University of Health Sciences, Karachi  
SENIOR DIRECTOR FINANCE  
(Member)  
Dow University of Health Sciences  
Karachi.



**PROF. DR. KARTAR DAWANI**  
Pro - Vice Chancellor  
Dow University of Health Sciences  
Karachi

**Professor Kartar Dawani**  
Pro-Vice Chancellor

Dow University of Health Sciences, Karachi  
(Chairman)



Proposed by  
M. I. Smouh Jung

Dated: 17<sup>th</sup> September, 2019

## MINUTES OF TECHNICAL BID OPENING MEETING

NIT No.	DUHS / DP / 2019 /-77 Dated: 8 <sup>th</sup> August, 2019
SPPRA (PPMS website)	Sr. # T00582-19-0002
Method and procedure of procurement	Single Stage – Two Envelope Procedure SPP Rules – 46(2)

### PROCUREMENT OF DRUGS / MEDICINES / NUTRITION / CONTRAST MEDIA & ALLIED ITEMS DOW UNIVERSITY OF HEALTH SCIENCES, KARACHI

Meeting of the Procurement Committee (PC) held for opening of **Technical Bids** on 17<sup>th</sup> September, 2019 in respect of subject NIT. Meeting was attended by members of the Procurement Committee and representative of the bidders. **(Attendance sheets are enclosed).**

The following bidders submitted their bids till the deadline of submission:

Sr.#	Name of Bidders	Sr.#	Name of Bidders
1	M/s. Hiranis Pharmaceutical (Pvt) Limited	25	M/s. United Agencies
2	M/s. Ali Gohar & Company (Pvt.) Ltd.	26	M/s. Spectrum Medical Supplies
3	M/s. Sami Pharmaceuticals (Pvt.) Ltd.	27	M/s. Shadani Enterprises
4	M/s. R.K. Chemical Company	28	M/s. Karachi Medical Company
5	M/s. Hassaan Distribution	29	M/s. Allmed Laboratories
6	M/s. Jawed Traders	30	M/s. Hussain Traders
7	M/s. Mabro International	31	M/s. Popular International (Pvt.) Ltd.
8	M/s. Saad Sales Services	32	M/s. Global Pharmaceuticals (Pvt.) Ltd.
9	M/s. Hamza Enterprises	33	M/s. National Agencies
10	M/s. R & A Enterprises	34	M/s. ACE Enterprises
11	M/s. Bosch Pharmaceuticals (Pvt.) Ltd.	35	M/s. Vision Pharmaceuticals (Pvt.) Ltd.
12	M/s. Z. I Enterprises	36	M/s. Hakimsons (Impex) Private Ltd.
13	M/s. Care and Cure Marketing Services	37	M/s. Lab Link Enterprises
14	M/s. Lavish Enterprises	38	M/s. Onco Pharma
15	M/s. Pioneer Distributors	39	M/s. Onco One
16	M/s. Graton Pharma	40	M/s. Pharmawell Pvt. Ltd.
17	M/s. Medie International	41	M/s. Roche Pakistan
18	M/s. Al Habib Pharmaceuticals	42	M/s. Hospital Solution
19	M/s. Trade Link	43	M/s. Gulf Pharmaceuticals
20	M/s. Faraz Associates	44	M/s. Intra Health

MINUTES OF TECHNICAL MEETING

  
Prof. Dr. Hassan Khan  
DEPUTY DIRECTOR FINANCE  
Dow University of Health Sciences  
Karachi

  
PROF. DR. KARTAR DAWANI  
Pro Vice Chancellor  
Dow University of Health Sciences  
Karachi

  
DR. AJAZA ZUREEDI  
Add. Medical Superintendent  
(Admin)  
Dr. Rub K. M. Pinar Civil Hospital Karachi

Sr.#	Name of Bidders	Sr.#	Name of Bidders
21	M/s. Shamim & Co.	45	M/s. Muller & Phipps Pakistan (Private) Ltd.
22	M/s. Waseem Brothers	46	M/s. Medco Health Care
23	M/s. Aster Life Sciences	47	M/s. Pharmasol (Pvt.) Ltd.
24	M/s. Hoffmann Human Health Pakistan Ltd.		

It was briefed to the participants that initially, only Technical Bids / Proposals will be opened and evaluated in a manner prescribed in bidding documents, without reference to the price and reject any proposal which does not conform to the specified requirements. Financial Bids / Proposals of technically qualified bids shall be opened publicly at a time, date and venue announced and communicated to the bidders in advance. Financial Bids / Proposals found technically disqualified / non-responsive shall be returned un-opened to the respective bidder(s). Accordingly, prior to evaluate bids in depth, preliminary examination of the bids was made by the procurement committee.

The Procurement Committee shall examine all the bids as per Qualification / Eligibility Criteria provided in bidding documents and verify the documents submitted by the bidders.

The meeting ended with the vote of thanks.



**Dr. Aijaz Zubedi**

Additional Medical Superintendent (Admin)  
Dr. Ruth K.M Pfau, Civil Hospital – Karachi  
(Member)

**DR. AIJAZ A. ZUBEDI**  
Add: Medical Superintendent  
(Admin)  
Dr. Ruth K.M. Pfau Civil Hospital Karachi




**Representative of Finance Directorate**  
Dow University of Health Sciences, Karachi  
(Member)

**PROF. DR. KARTAR DAWANI**  
Pro-Vice Chancellor  
Dow University of Health Sciences  
Karachi

**Professor Kartar Dawani**  
Pro-Vice Chancellor

Dow University of Health Sciences, Karachi  
(Chairman)



  
Prepared by  
M. Ismail Javeed

## ANNEXURE - A

## CRITERIA FOR EVALUATION OF THE BID

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT No. DUHS/DP/2019/77 Dated 08 August 2019

TECHNICAL BIDS OPENED ON 17 September 2019

## Section - A

Sr. No.	Description	1	2	3	4	5	6	7
		Copy of Registration National Tax Number (NTN) (Mandatory) / General Sale Tax (GST) (if applicable). Bidder should be active Tax Payer and Filer	Copy of Undertaking regarding supply of required items within stipulated time with quality certificate from the authorized Laboratory.	Average Financial Turn-over for the last Three Fiscal Years Rs. 100 Million or more regarding financial Return Forms of Last Three Years	Relevant experience (Documentary Evidence should be attached) for the last three years with large Hospitals.	An undertaking regarding that the Firm shall not be black listed / involve in any litigation with Government Institutions. (Federal / Provincial / Local)	Valid Drug Sales License whichever is applicable is the mandatory requirement of the bid.	Remarks
1	M/s. Hiranis Pharmaceutical (Pvt) Limited	Yes	Yes	Yes	Yes	Yes	Yes	
2	M/s. Ali Gobbar & Company (Pvt.) Ltd	Yes	Yes	Yes	Yes	Yes	Yes	
3	M/s. Sami Pharmaceuticals (Pvt.) Ltd	Yes	Yes	Yes	Yes	Yes	Yes	
4	M/s. R.K. Chemical Company	Yes	Yes	Yes	Yes	Yes	Yes	
5	M/s. Hissan Distribution	Yes	Yes	Yes	Yes	Yes	Yes	
6	M/s. Jawed Traders	Yes	Yes	Yes	Yes	Yes	Yes	
7	M/s. Mabro International	Yes	Yes	Yes	Yes	Yes	Yes	
8	M/s. Saad Sales Services	Yes	Yes	Yes	Yes	Yes	Yes	
9	M/s. Hamza Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
10	M/s. R. & A Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
11	M/s. Bosch Pharmaceuticals (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	
12	M/s. Z. I Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
13	M/s. Care and Cure Marketing Services	Yes	Yes	Yes	Yes	Yes	Yes	
14	M/s. Laviah Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
15	M/s. Pioneer Distributors	Yes	Yes	Yes	Yes	Yes	Yes	







Sr. No.	Description	Copy of Registration National Tax Number (NTN) (Mandatory) / General Sale Tax (GST) (if applicable). Bidder should be active	Copy of Undertaking regarding supply of required items within stipulated time with quality certificate from the authorized Laboratory.	Average Financial Turn-over for the last Three Fiscal Years Rs. 100 Million or more regarding financial soundness of the firm. Income Tax Return Forms of Last Three Years must be attached	Relevant experience (Documentary Evidence should be attached) for the last three years with large Hospitals.	An undertaking regarding that the Firm shall not be black listed / involve in any litigation with Government Institutions. (Federal / Provincial / Local)	Valid Drug Sales License whichever is applicable is the mandatory requirement of the bid.	Remarks
16	M/s. Gration Pharma	Yes	Yes	Yes	Yes	Yes	Yes	
17	M/s. Medie International	Yes	Yes	Yes	Yes	Yes	Yes	
18	M/s. Al Habib Pharmaceuticals	Yes	Yes	Yes	Yes	Yes	Yes	
19	M/s. Trade Link	Yes	Yes	Yes	Yes	Yes	Yes	
20	M/s. Faraz Associates	Yes	Yes	Yes	Yes	Yes	Yes	
21	M/s. Shamim & Co.	Yes	Yes	Yes	Yes	Yes	Yes	
22	M/s. Wassam Brothers	Yes	Yes	Yes	Yes	Yes	Yes	
23	M/s. Aster Life Sciences	Yes	Yes	Yes	Yes	Yes	Yes	
24	M/s. Hoffmann Humon Health Pakistan Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	
25	M/s. United Agencies	Yes	Yes	Yes	Yes	Yes	Yes	
26	M/s. Spectrum Medical Supplies	Yes	Yes	Yes	Yes	Yes	Yes	
27	M/s. Shadian Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
28	M/s. Karachi Medical Company	Yes	Yes	Yes	Yes	Yes	Yes	
29	M/s. Alimud Laboratories	Yes	Yes	Yes	Yes	Yes	Yes	
30	M/s. Hanaain Traders	Yes	Yes	Yes	Yes	Yes	Yes	
31	M/s. Popular International (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	
32	M/s. Global Pharmaceuticals (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	
33	M/s. National Agencies	Yes	Yes	Yes	Yes	Yes	Yes	
34	M/s. ACT Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
35	M/s. Vision Pharmaceuticals (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	


Sr. No.	Description	Copy of Registration National Tax Number (NTN) (Mandatory) / General Sale Tax (GST) (if applicable). Bidder should be active Tax Payer and Filer	Copy of Undertaking regarding supply of required items within stipulated time with quality certificate from the authorized Laboratory.	Average Financial Turn-over for the last Three Fiscal Years Rs. 100 Million or more regarding financial soundness of the firm. Income Tax Return Forms of Last Three Years must be attached	Relevant experience (Documentary Evidence should be attached) for the last three years with large Hospitals.	An undertaking regarding that the Firm shall not be black listed / involve in any litigation with Government Institutions, (Federal / Provincial / Local)	Valid Drug Sales License whichever is applicable is the mandatory requirement of the bid.	Remarks
36	M/s. Hakimsons (Impex) Private Ltd	Yes	Yes	Yes	Yes	Yes	Yes	
37	M/s. Lab Link Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	
38	M/s. Onco Pharma	Yes	Yes	Yes	Yes	Yes	Yes	
39	M/s. Onco One	Yes	Yes	Yes	Yes	Yes	Yes	
40	M/s. Pharmawell Pvt. Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	
41	M/s. Roche Pakistan	Yes	Yes	Yes	Yes	Yes	Yes	
42	M/s. Hospital Solution	Yes	Yes	Yes	Yes	Yes	Yes	
43	M/s. Gulf Pharmaceuticals	Yes	Yes	Yes	Yes	Yes	Yes	
44	M/s. Intra Health	Yes	Yes	Yes	Yes	Yes	Yes	
45	M/s. Muller & Phipps Pakistan (Private) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	
46	M/s. Medco Health Care	Yes	Yes	Yes	Yes	Yes	Yes	
47	M/s. Pharmaol (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	








**ANNEXURE - A**

**CRITERIA FOR EVALUATION OF THE BID**

**Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items**





**NIT No. DUHS/DP/2019/77 Dated 08 August 2019**

**TECHNICAL BIDS OPENED ON 17 September 2019**

**Section - b**

**FOR PHARMACEUTICALS**

Sl No.	Description	Previous performance in the DUHS (last three years)						Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
		i	ii	iii	iv	v	vi	vii	viii	ix					
1	M/s. Hiranis Pharmaceutical (Pvt) Limited	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2	M/s. Ali Gohar & Company (Pvt.) Ltd.														
3	M/s. Sami Pharmaceuticals (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4	M/s. R.K. Chemical Company	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	i) M/s Bio Labs (Pvt) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Pfizer Pakistan Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s Wiyeth Pakistan Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Novartis Pharma (Pak)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5	M/s. Hassaan Distribution														
	i) M/s. Pacific	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s. Adamjee	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s. Sehazoo Zaka	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6	M/s. Javed Traders														
	i) M/s Hudson Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s. S J & G Fazal Elahi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s. Semios Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Sr. No.	Description	Previous performance in the DTHS (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
8	M/s. Saad Sales Services	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	i M/s Abbott Laboratories									
9	M/s. Hamza Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	i M/s. Mass Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10	M/s. R & A Enterprises									
	i M/s Medipak Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii M/s Swiss Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii M/s Allimed Pvt Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv M/s Cirin Pharma ICI	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v M/s Bio Labs (Pvt) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vi M/s Willshire Lab	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vii M/s SI & G (Pvt) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11	M/s. Bosch Pharmaceuticals (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	M/s. Z. I Enterprises									
	i M/s S.J & G Fazal Ellahi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii M/s Glaxo Smith Kline	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii M/s Searle	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
iv	M/s Chiesi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
13	M/s. Care and Cure Marketing Services									
	i M/s RGP (Pak)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii M/s Amaranat	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv M/s Glaxo Smith Kline	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v M/s Chiesi (Italy)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vi M/s Servier	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes






Sr. No.	Description	Previous performance in the D/H/S (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
14	M/s. Lavish Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	i M/s Zafra Pharma									
15	M/s. Pioneer Distributors	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	i M/s Pharmatec (Pvt) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii M/s Biogenics (Pvt) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii M/s Kaizen Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17	M/s Pfizer Pakistan Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	M/s. Medic International									
19	i M/s Indus Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii M/s Bayer Pakistan (Pvt)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii M/s Medinostic Healthcare	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
19	M/s. Trade Link									
	i M/s Sanofi Aventis	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii M/s Hillon Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii M/s Merck	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv M/s Martin Dow	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v M/s Highnoon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vi M/s CCL	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
vii M/s Matrix	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	





  
 10/8/2018  


Sr. No.	Description	Previous performance in the DTHS (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
20	M/s. Faraz Associates									
	i) M/s USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	M/s. Shamim & Co.									
	i) M/s Ambrosia Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Barret Hodgson Pak	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s EZEM CORP. USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Ferozsons Lab Ltd	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v) M/s Getz Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vi) M/s Glitz Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vii) M/s Helix Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	viii) M/s Helix Pharma Kyc	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ix) M/s Houms Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	x) M/s Novartis Pharma (Sandoz)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	xi) M/s Otsuka	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	xii) M/s Peru South America	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	xiii) M/s Scilife Pharma (Ps) Ltd	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	xiv) M/s Siza Int. Lhr	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	xv) M/s Tele-Paper SDN Malaysia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	xvi) M/s Uroguay	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes



  

  

  




Sr. No.	Description	Previous performance in the DUHS (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio- availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Form	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
23	M/s. Aster Life Sciences									
	i) M/s Hamaz Pharma (Pvt)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
25	M/s. United Agencies									
	i) M/s China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
26	M/s. Spectrum Medical Supplies									
	i) M/s Alco Laboratories Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
27	M/s. Shadani Enterprises									
	i) M/s Mactor Int.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s BF Biosciences	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s Sante	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Next Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
v) M/s Stancos	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
28	M/s. Karnchi Medical Company									
	i) M/s Surge Laboratories	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Nabiqasim (Pvt.) Ltd	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
29	M/s. Allmed Laboratories									
	iii) M/s Allmed Pvt Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

10/8/2010  
 10/8/2010

Sl. No.	Description	Previous performance in the DLHS (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Form	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
<b>30</b>	<b>M/s. Hussain Traders</b>									
i	M/s Bio Sidas SA (Searle Biosciences)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ii	M/s Biotech Pharma Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
iii	M/s Cureva Health Pvt (Highmoon Lab)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
iv	M/s Deva Holding A.S (Bio Sciences)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
v	M/s Gador S.A (Searle Biosciences)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
vi	M/s Horizon Healthcare Pvt	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
vii	M/s Ildong Pharma (Searle Biosciences)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
viii	M/s Korea Pharma Seoul South Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ix	M/s Kyng Dong Pharma Seoul Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
x	M/s Leo Pharma Denmark	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xi	M/s Medisave Pharma (Searle Biosciences)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xii	M/s Nabiqasim Ind. (Pvt.) Ltd	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xiii	M/s Nexter Pharma (Searle Biosciences)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xiv	M/s OBS Pakistan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xv	M/s Searle IV Solution (Pvt) Ltd	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xvi	M/s The Searle Company	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xvii	M/s Vifor (Int) Ltd. Switzerland	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
xviii	M/s Xellia Pharma Denmark	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>32</b>	<b>M/s. Global Pharmaceuticals (Pvt.) Ltd.</b>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

  
 10/8/2018
   

  


Sr. No.	Description	Previous performance in the DUIS (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material	
33	M/s. National Agencies	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
											i M/s FDI,
											ii M/s Brooks Pharma
											iii M/s Bio-Labs
											iv M/s Mactor Int.
											v M/s ICI Pakistan
34	M/s. ACE Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
											i M/s Novartis Pharma (Pak)
35	M/s. Vision Pharmaceuticals (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
37	M/s. Lab Link Enterprises	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
											i M/s AGP Ltd.
38	M/s. Onco Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
											vi M/s Seaple Pakistan
39	M/s. Onco One	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
											i M/s Pharmedic Pakistan
40	M/s. Pharmawell Pvt. Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
											i M/s North China Co. Ltd.




  
 10/21/2018  
 number

Sr. No.	Description	Previous performance in the DHHS (last three years)	Federal Drug Inspector / Drug Licensing Board (Rating) of last three years	Financial Soundness of the Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
41	M/s. Roche Pakistan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
42	M/s. Hospital Solution									
	i) M/s Shaigan Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Geofman Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s Amsons Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Saffron Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v) M/s Novumed Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	vi) M/s Reckitt Benckiser	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
43	M/s. Gulf Pharmaceuticals	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
45	M/s. Muller & Phipps Pakistan (Private) Limited.									
	ii) M/s Ali Gohar	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
46	M/s. Medco Health Care									
	i) M/s Renacon Pharma Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
47	M/s. Pharmasol (Pvt.) Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes



  
 10/18/2016



**ANNEXURE - A**

**CRITERIA FOR EVALUATION OF THE BID**

Procurement of Drugs / Medicines / Nutrition / Contrast Media and Allied Items

NIT No. DUHS/DP/2019/77 Dated 08 August 2019

TECHNICAL BIDS OPENED ON 17 September 2019

**Section - b**  
**FOR IMPORTERS**

Sr. No.	Description	i	ii	iii	iv	v	vi	vii	viii	ix	
		Previous performance in the DUHS (last three years)	Company agreement with principal duty countersigned by Pakistan Embassy/Consulates (if applicable)	Financial Soundness of the Distributor/Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material	
7	M/s. Mabro International i M/s Tristel Solution UK ii M/s Promark iii M/s Guest Medical iv M/s Kuzey Saglik v M/s Gojo Industries USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
8	M/s. Saad Sales Services. ii M/s Dae Han New Pharma Korea iii M/s Fada Pharma Argentina iv M/s Probiomed Mexico v M/s Hangzhu Co. Ltd China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12	M/s. Z. I Enterprises iv M/s Chiesi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

*[Handwritten signatures and initials in blue ink]*

Sr. No.	Description	i	ii	iii	iv	v	vi	vii	viii	ix	
		Previous performance in the DHHS (last three years)	Company agreement with principal duty counterparty (Embassy/Consulates (if applicable))	Financial Soundness of the Distributor/Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material	
13	M/s. Care and Cure Marketing Services										
		ii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		v	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		vii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
16	M/s. Graton Pharma		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		i	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		ii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
18	M/s. Al Habib Pharmaceuticals		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		i	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		ii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
21	M/s. Shamim & Co.		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		i	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		ii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
22	M/s. Waseem Brothers		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		iii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		i	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		ii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		iii	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	M/s. Abbott USA	iv	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
		v	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	

*[Handwritten signature]*

10/8/2024  
*[Handwritten signature]*

*[Handwritten signature]*

Sr. No.	Description	i	Company agreement with Principal duty counterigned by Pakistan Embassy/Consulates (if applicable)	iii	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	v	Warehouse assessment as per attached Performa	vii	Market Share more than 50% of the product in comparison to Government	viii	Government Share more than 50% of the product in comparison to market	ix	Source of Raw Material
		Previous performance in the DUHS (last three years)	ii	Financial Soundness of the Distributor/Company	iv	Quality Control Department Assessment	vi	of the product in comparison to Government	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material		
24	0												
	<b>M/s. Hoffmann Human Health Pakistan Limited</b>												
	i M/s Myungmoon Pharma Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	ii M/s Serum Institute of India	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iii M/s Chong Kun Dang Pharma S.Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iv M/s CSPC China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
23	<b>M/s. Aster Life Sciences</b>												
	ii M/s LG Chem Ltd. South Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iii M/s Beijing SL Pharma China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iv M/s Chong Kun Dang Pharma S.Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	v M/s NCPC China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
24	<b>M/s. Hoffmann Human Health Pakistan Limited</b>												
	i M/s Myungmoon Pharma Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	ii M/s Serum Institute of India	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iii M/s Chong Kun Dang Pharma S.Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iv M/s CSPC China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
25	<b>M/s. United Agencies</b>												
	ii M/s Leo Denmark	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
	iv M/s Bayer Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	



Sr. No.	Description	0								
		i	ii	iii	iv	v	vi	vii	viii	ix
		Previous performance in the DTHS (last three years)	Company agreement with principal duty counterigned by Pakistan Embassy/Consulates (if applicable)	Financial Soundness of the Distributor/Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
29	M/s. Allimed Laboratories									
	i) M/s Neovij Biotech Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Pharmacosmos Denmark	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Dr. Franz Kohler chemie	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v) M/s Tech Pool China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
31	M/s. Popular International (Pvt.) Ltd.									
	i) M/s Grifols Therapeutics USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Kedrion Italy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
36	M/s. Shanghai Raas Blood Product Co. Ltd China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	M/s. Hakimsons (Impex) Private Ltd.									
37	M/s. Lab Link Enterprises									
	i) M/s CSL, Biotherapies Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	ii) M/s Bharat Serum & Vaccine India	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
38	M/s. Onco Pharma									
	i) M/s Astra Zeneca USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
39	M/s Hospira Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s Pfizer Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Actavis Italy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
40	M/s Astra Zeneca UK Ltd	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes


Sr. No.	Description	0								
		i	ii	iii	iv	v	vi	vii	viii	ix
		Previous performance in the DLHS (last three years)	Company agreement with principal duty counterigned by Pakistan Embassy/Consulates (If applicable)	Financial Soundness of the Distributor/Company	Assay procedure / References Standard / Evidence of Bio-availability / Bio Equivalence	Quality Control Department Assessment	Warehouse assessment as per attached Performa	Market Share more than 50% of the product in comparison to Government	Government Share more than 50% of the product in comparison to market	Source of Raw Material
39	M/s. Onco One									
	ii) M/s. Aquida GMBH Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iii) M/s Pharmidea SLA Latvia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	iv) M/s Celon Lab, India	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	v) M/s Delpharm Tours France	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
40	M/s. Pharmawell Pvt. Ltd.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
41	M/s. Roche Pakistan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
42	M/s. Hospital Solution									
	vii) M/s GIBL Turkey	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
43	M/s. Gulf Pharmaceuticals	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
44	M/s. Intra Health									
	i) M/s Antiseptica Chem Pharmia Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
45	M/s. Muller & Phipps Pakistan (Private) Limited.									
	i) M/s Novo Nordisk Pharma	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
47	M/s. Pharmasol (Pvt.) Ltd.									

  
 10/8/2018  
